Margo Cohen
Principal investigator.
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
1990First federal award
$6.6MFederal grants as PI22 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
22 awards · $6.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 1, 2005 | NIH | SBIR/STTR Phase II LDL Modification in Diabetic Complications | $641K | — |
| Aug 1, 2005 | NIH | SBIR/STTR Phase I LDL Modification and Diabetic Renal Dysfunction | $104K | — |
| Aug 1, 2005 | NIH | SBIR/STTR Phase II LDL Modification in Diabetic Complications | $1.1M | — |
| Jul 1, 2003 | NIH | SBIR/STTR Phase II Reducing Renal TGF-B in Diabetic Glomerulosclerosis | $250K | — |
| Jul 1, 2003 | NIH | SBIR/STTR Phase II Reducing Renal TGF-B in Diabetic Glomerulosclerosis | $264K | — |
| Jul 1, 2003 | NIH | SBIR/STTR Phase II Reducing Renal TGF-B in Diabetic Glomerulosclerosis | $601K | — |
| Jul 1, 2003 | NIH | SBIR/STTR Phase II Reducing Renal TGF-B in Diabetic Glomerulosclerosis | $636K | — |
| Aug 1, 2002 | NIH | SBIR/STTR Phase I Reducing Renal TGF-B in Diabetic Glomerulosclerosis | $100K | — |
| Jun 15, 2002 | NIH | SBIR/STTR Phase II Point-of-Care Measurement of Glycated Hemoglobin | $430K | — |
| Jun 15, 2002 | NIH | SBIR/STTR Phase II Point-of-Care Measurement of Glycated Hemoglobin | $288K | — |
| Jun 15, 2002 | NIH | SBIR/STTR Phase I Point-of-Care Measurement of Glycated Hemoglobin | $100K | — |
| May 1, 1998 | NIH | SBIR/STTR Phase II NOVEL AGENTS TO PREVENT KIDNEY DISEASE IN DIABETES | $369K | — |
| May 1, 1998 | NIH | SBIR/STTR Phase II NOVEL AGENTS TO PREVENT KIDNEY DISEASE IN DIABETES | $243K | — |
| May 1, 1998 | NIH | SBIR/STTR Phase I NOVEL AGENTS TO PREVENT KIDNEY DISEASE IN DIABETES | $100K | — |
| Apr 7, 1997 | NIH | SBIR/STTR Phase II DIABETIC RETINOPATHY--THERAPY WITH GLYCATION INHIBITORS | $296K | — |
| Jul 1, 1992 | NIH | SBIR/STTR Phase II IMMUNOASSAYS FOR GLYCOALBUMIN WITH MONOCLONAL ANTIBODY | $225K | — |
| Jul 1, 1992 | NIH | SBIR/STTR Phase II IMMUNOASSAYS FOR GLYCOALBUMIN WITH MONOCLONAL ANTIBODY | $232K | — |
| Sep 30, 1991 | NIH | SBIR/STTR Phase II MONOCLONAL ANTIBODY IMMUNOASSAYS FOR GLYCOHEMOGLOBIN | $250K | — |
| Sep 30, 1991 | NIH | SBIR/STTR Phase II MONOCLONAL ANTIBODY IMMUNOASSAYS FOR GLYCOHEMOGLOBIN | $183K | — |
| Sep 5, 1991 | NIH | SBIR/STTR Phase I MEASUREMENT OF GLYCATED LDL WITH MONOCLONAL ANTIBODIES | $50K | — |
| Jun 1, 1990 | NIH | SBIR/STTR Phase I IMMUNOASSAY FOR HEMOGLOBIN A1C WITH MONOCLONAL ANTIBODY | $49K | — |
| Mar 1, 1990 | NIH | SBIR/STTR Phase I IMMUNOASSAY FOR GLYCOALBUMIN WITH MONOCLONAL ANTIBODY | $48K | — |
Peer ranks
Federal funding#38
Awards as PI#9
Patents#27
Companies
No tracked company linked yet.
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.